loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Nifurtimox

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Nifurtimox

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 35,368Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    U.S. Food and Drug Administration Approves Lampit® (nifurtimox)
    U.S. Food and Drug Administration Approves Lampit® (nifurtimox)

    07 Aug 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200807005073/en

    BUSINESSWIRE
    07 Aug 2020
    Share Share
    Bayer's Phase III Clinical Trial Of Nifurtimox In Pediatric Patients
    Bayer's Phase III Clinical Trial Of Nifurtimox In Pediatric Patients

    15 Mar 2019

    // PRNECASWIRE.COM/NEWS-RELEASES/BAYERS-PHASE-III-CLINICAL-TRIAL-OF-NIFURTIMOX-IN-PEDIATRIC-PATIENTS-WITH-CHAGAS-DISEASE-MEETS-PRIMARY-ENDPOINT-300812233

    https://www.prnewswire.com/news-releases/bayers-phase-iii-clinical-trial-of-nifurtimox-in-pediatric-patients-with-chagas-disease-meets-primary-endpoint-300812233.html

    PRNECASWIRE.COM/NEWS-RELEASES/BAYERS-PHASE-III-CLINICAL-TRIAL-OF-NIFURTIMOX-IN-PEDIATRIC-PATIENTS-WITH-CHAGAS-DISEASE-MEETS-PRIMARY-ENDPOINT-300812233
    15 Mar 2019
    Share Share
    Bayer's PhIII Clinical Trial Of Nifurtimox In Pediatric Patients
    Bayer's PhIII Clinical Trial Of Nifurtimox In Pediatric Patients

    14 Mar 2019

    // BIOSPACE

    https://www.biospace.com/article/releases/bayer-s-phase-iii-clinical-trial-of-nifurtimox-in-pediatric-patients-with-chagas-disease-meets-primary-endpoint/

    BIOSPACE
    14 Mar 2019
    Share Share